Masimo SET ® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 ...
CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo Signal Extraction Technology® (SET®) pulse ...
The INSPIRE Trial Prospectively Assesses Pulse Oximeter Accuracy Using a Unique Real-world Study Design and in the Feasibility Study Showed No Clinically Significant Bias Between Patients with Light ...
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient ...
Masimo has raised the stakes in its escalating pulse oximetry-focused feud with competitor Covidien. And the game is beginning to get interesting. As part of a campaign to "help clinicians separate ...
In Feasibility Study for Large, Prospective, Real-World Trial, Masimo SET® Performed Accurately on Critically Ill Adult ICU Patients of All Skin Tones The INSPIRE Trial Prospectively Assesses Pulse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results